

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/572,027	8/572,027 12/14/1995		LORIN R. DEBONTE	A21-535.1007	3481	
26191	7590	01/13/2005		EXAM	EXAMINER	
FISH & RIC	HARDS	ON P.C.	MCELWAIN, ELIZABETH F			
3300 DAIN R	AUSCHI	ER PLAZA				
60 SOUTH S	IXTH ST	REET	ART UNIT	PAPER NUMBER		
MINNEAPOLIS, MN 55402				1638		

DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	08/572,027	DEBONTE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Elizabeth F. McElwain	1638				
The MAILING DATE of this communication apperent of the Period for Reply	ears on the cover sheet with the c	orrespond nce address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) ⊠ Responsive to communication(s) filed on 8/26/03,6/24/04 and 10/23/04. 2a) ⊠ This action is FINAL. 2b) ☐ This action is non-final. 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
 4) Claim(s) 1-3,5-8,10,27-29,31-35,37-46 and 55-70 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-3,5-8,10,27-29,31-35,37-46 and 55-70 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 						
Application Papers						
 9) The specification is objected to by the Examiner 10) The drawing(s) filed on 14 December 1995 is/an Applicant may not request that any objection to the d Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner 	e: a) \square accepted or b) \square objectoration of second accepted or by acceptance. See on is required if the drawing(s) is object.	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	te				

Application/Control Number: 08/572,027

Art Unit: 1638

DETAILED ACTION

The amendment filed October 23, 2004 and the responses filed August 26, 2003 and June 24, 2004 have been entered.

Claims 3, 5, 6, 10, 29, 32, 35, 40, 46, 55, 57, 62, 64 and 66 are currently amended.

Claims 4, 9, 11-26, 30, 36 and 47-54 are cancelled.

Claims 1-3, 5-8, 10, 27-29, 31-35, 37-46 and 55-70 are pending and are examined on the merits.

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-8 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3 and 47-54 of copending Application No. 09/771,904. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claimed nucleic acids and plants having

Art Unit: 1638

a mutation in the specified motif would have been obvious over the claimed nucleic acids and plants having a mutation in the specified motif.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 112

- 4. Claims 1-3, 5-8, 10, 27-29, 31-35, 37-46 and 55-70 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, as stated in the last office action.
- 5. Applicant's arguments filed August 26, 2003 have been fully considered but they are not persuasive. Applicants assert that the specification provides sufficient written description for the claimed nucleic acid fragments, pointing to portions of the specification at pages 14-15 and Tables 1-5, which describe the conserved motifs of delta-12 and delta-15 desaturases from different species. Applicants further argue that the specification provides examples of mutated motifs, for plants and methods of producing plant lines.
- 6. The Examiner maintains that the rejection is proper given that applicant does not describe fragments as small as 20 nucleotides that encode mutant delta-12 or delta-15 fatty acid desaturases. Therefore, plants and methods of making mutant plants are similarly not described, as stated in the last office action.

- 7. Claims 1-3, 5-8, 10, 27-29, 31-35, 37-46 and 55-70 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, as stated in the last office action.
- 8. Applicant's arguments filed August 26, 2003 have been fully considered but they are not persuasive. Applicants assert that the specification provides detailed guidance to make and use the claimed nucleic acids and plants.
- 9. The Examiner maintains that the rejection is proper given that the disclosed plants were isolated by mutagenesis and introducing mutations is not a repeatable method for obtaining a plant, and applicant has not taught how to use the claimed nucleic acids, as stated in the last office action, and it would require undue experimentation to practice the claimed invention.
- 10. Claims 55, 57, 62 and 64 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 55, 57, 62 and 64 remains rejected for the recitation of "plant line" at step (d), given that steps are missing in the claim for the production of a plant line in step (d).

Applicant's arguments filed August 26, 2003 have been fully considered but they are not persuasive. Applicants assert that the specification provides methods for producing plant

Art Unit: 1638

lines. However, the Examiner maintains that no step for producing a plant line is provided in the claim.

All other rejections of the claims under 35 U.S.C. 112, second paragraph set forth in the last office action have been withdrawn in view of amendments or cancellation of the claims.

11. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth F. McElwain whose telephone number is (571) 272-0802. The examiner can normally be reached on increased flex time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 08/572,027 Page 6

Art Unit: 1638

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elizabeth F. McElwain, Ph.D.

Primary Examiner Art Unit 1638

EFM